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Abstract
Introduction: Despite significant progress in improving access to antiretroviral therapy over the past decade, substantial numbers
of people living with HIV (PLHIV) in all regions continue to experience severe illness and require hospitalization. We undertook a
global review assessing the proportion of hospitalizations and in-hospital deaths because of tuberculosis (TB) in PLHIV.
Methods: Seven databases were searched to identify studies reporting causes of hospitalizations among PLHIV from 1 January
2007 to 31 January 2015 irrespective of age, geographical region or language. The proportion of hospitalizations and in-hospital
mortality attributable to TB was estimated using random effects meta-analysis.
Results: From an initial screen of 9049 records, 66 studies were identified, providing data on 35,845 adults and 2792 children
across 42 countries. Overall, 17.7% (95% CI 16.0 to 20.2%) of all adult hospitalizations were because of TB, making it the leading
cause of hospitalization overall; the proportion of adult hospitalizations because of TB exceeded 10% in all regions except the
European region. Of all paediatric hospitalizations, 10.8% (95% CI 7.6 to 13.9%) were because of TB. There was insufficient data
among children for analysis by region. In-hospital mortality attributable to TB was 24.9% (95% CI 19.0 to 30.8%) among adults
and 30.1% (95% CI 11.2 to 48.9%) among children.
Discussion: TB remains a leading cause of hospitalization and in-hospital death among adults and children living with HIV
worldwide.
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Introduction
Tuberculosis (TB) remains a leading cause of HIV-associated
mortality andmorbidity among both adults and childrenworld-
wide [1,2]. In 2013, an estimated 1.1 million of the 9.0 million
people who developed TB worldwide were HIV-positive, and
there were 360,000 deaths from HIV-associated TB [3]. Among
people initiating antiretroviral therapy (ART), incident TB is
associated with poorer virological outcomes and a higher risk
of early mortality [46], with autopsy studies suggesting that
TB is the cause of death in over a third (37%) of adult persons
living with HIV (PLHIV) in sub-Saharan Africa [7].
Recent studies from both low- [8,9] and high-income
settings [10,11] have reported that TB contributes substan-
tially to hospitalization among people living with HIV, and
mortality among those hospitalized is high [12]. The primary
aim of this review was to determine the proportion of hos-
pitalizations and in-hospital deaths among HIV-positive adults
and children attributable to TB worldwide and by World
Health Organization (WHO) geographic region.
Methods
This study is a sub-analysis of data collected as part of a
global systematic review of causes of hospitalization among
HIV-positive patients. The full methodology of the study is
explained elsewhere [12]. Briefly, two investigators (NF, ZS)
working independently and in duplicate searched Medline via
PubMed, Embase, Web of Science, LILACS, AIM, IMEMR and
WPIMR from inception up to 31 January 2015. The investiga-
tors also screened all International AIDS Society conferences
up to Melbourne, 2014. Consensus was achieved to resolve
discrepancies. Investigators followed a study protocol avail-
able from the corresponding author; the search strategy is
provided in the Supplementary file. Studies were considered
eligible if they included TB among the reported causes of
hospitalization within a cohort of at least 20 HIV-positive
hospitalized patients. In order to focus on data following
ART scale-up, we sought data reported after 1 January 2007;
studies reporting causes of hospitalization prior to 2007
were included if the majority (50%) of hospitalizations
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occurred after 2007. The same investigators extracted dupli-
cate data on the number of HIV-positive patients hospitalized
for TB and the number of patients who died of TB during
hospitalization, among all HIV-positive hospitalized patients.
Data were also extracted on study setting, patient age (adults
and children, as defined by the studies), prior knowledge
of HIV status, length of hospital stay, method of TB diagnosis
and usage of ART and isoniazid preventive therapy (IPT) at
admission. For all reported causes of hospital admission and
in-hospital mortality, proportions and 95% confidence inter-
vals were calculated. Data were pooled following transforma-
tion to stabilize the variance in the raw proportions [13,14]
using random effects meta-analysis [15]. The analyses were
conducted disaggregated by age (adults vs children) and
WHO geographical region (www.who.int/about/regions/en/).
Meta-regression was used to explore the potential influence
of ART status and calendar year on TB hospitalization. For
adult studies, subgroup analyses explored the potential influ-
ence of diagnostic method (there was insufficient information
for this to be assessed for children). All data were analyzed
in Stata version 12.0.
Results
From an initial screen of 9049 titles and abstracts, 66 studies
were included in the final review. These studies were carried
out in 42 countries, across all WHO regions (Figure 1). Char-
acteristics of studies included in this review are summarized
in the Supplementary file.
For adults, 51 studies reported 5497 cases of TB as a
cause of hospitalization among 35,845 adult patients. Studies
were carried out in 42 countries across all regions. Among all
HIV-positive hospitalized patients, median age was 37 years
(interquartile range [IQR] 35 to 40 years), median length
of stay was 12 days (IQR, 7 to 16 days) and median CD4 at
hospitalization was 131 cells/mm3 (IQR 76 to 199 cells/mm3).
The proportion of adults on ART at time of hospitalization did
not change over time. Pulmonary TB was mainly diagnosed
by clinical assessment supported by at least one laboratory
finding (65% of studies reporting this information), whereas
for children diagnosis was generally based on clinical diagnosis
alone (Supplementary file). Clinical diagnosis of extrapul-
monary TB in adults was variously supported by examination
of cerebrospinal fluid, non-response to presumptive broad-
spectrum antibiotic treatment, radiological examination and
lymph node biopsy. Around a third (31.9%) of all adult patients
were newly diagnosed as HIV-positive at the time of hos-
pitalization. Only two studies reported use of IPT; both
reported that no patients were on IPT at time of admission.
The overall proportion of adult hospitalizations because of
TB was 17.7% (95% CI 16.0 to 20.2%) with regional variations
(Figure 2). This proportion was 22.3% (95% CI 15.8 to 28.8%)
when the analysis was restricted to studies in which TB was
diagnosed by clinical assessment supported by at least one
laboratory finding. Two-thirds of these hospitalizations were
because of pulmonary TB (66.6%; 95% CI 55.7 to 77.5%).
A high level of within-region variability was also observed; for
example, in the African region, TB as a cause of hospitaliza-
tion ranged from 8.1% to 41.0%. In order to assess whether
the overall result was influenced by the inclusion of older
studies, we ran a sensitivity analysis in which all studies
reporting data prior to 2009 were dropped from analy-
sis; the proportion of patients hospitalized because of TB
was not significantly different from the overall result (23.8%;
95% CI 18.0 to 29.6%).
9049 titles & abstract 
screened 
179 full text articles screened
8 Articles included from 
bibliography screen
1 unpublished study 
provided by author
66 studies included in final 
review
8870 excluded
Duplicates or not 
relevant to study 
question
122 excluded after full text 
review 
26 Most data reported <2007
13 Duplicate reports
4 Verbal autopsy studies
22 non-hospital studies
14 Denominator not 
reported
16 studies did not provide 
data on TB
12 studies reported multiple 
hospitalizations
15 Other reasons
Figure 1. Study selection process.
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Twenty seven studies reported cause of death. There
were 2376 deaths reported among 16,647 hospitalized adults
(pooled proportion for deaths among those hospitalized:
24.9%; 95% CI 19.0 to 30.8%), among which 620 were because
of TB (pooled proportion of TB deaths among all deaths:
27.3%; 95% CI 21.4 to 33.3%); 29.3% (95% CI 20.2 to 38.4%) of
adults hospitalized for TB were reported to have died of TB.
These results did not differ when the analysis was restricted
to studies in which TB was diagnosed by clinical assessment
supported by at least one laboratory finding.
Twenty seven studies reported ART status among adults
at admission. The median proportion on ART was 37.5% (IQR
13.8 to 45.5%). In meta-regression, the proportion of adult
patients hospitalized for TB decreased as ARTcoverage among
those hospitalized increased (pB0.001). There was no change
in the proportion of hospitalizations because of TB over time.
For children, 15 studies reported 292 cases of TB as a cause
of hospitalization among 2792 children across 15 countries, all
in low- and middle-income settings. Median length of stay was
10 days (IQR 9 to 11 days). Median age was five years (IQR 3 to
7 years). Only a minority of studies (5/14) reported CD4 cell
count: the median ranged from 151 to 845 cells/mm3. Over a
quarter (26.9%) of all paediatric patients were newly diag-
nosed as HIV-positive at the time of hospitalization. As for
adults, the proportion of children on ART at time of hos-
pitalization did not change over time.
The proportion of hospitalizations because of TB was 10.8%
(95% CI 7.6 to 14.0). There was only one documented case of
extrapulmonary TB. ART coverage among those hospitalized
was associated with a lower proportion of TB as cause of
admission, but this did not reach statistical significance be-
cause of the limited distribution of data (i.e. most children
were on ART at admission). Overall, 431 hospitalized children
died (pooled proportion for deaths among those hospitalized:
18.8%; 95% CI 8.1 to 29.5%); among whom 30.1% (95% CI
11.2 to 48.9%) died of TB; 45.4% (95% CI 6.0 to 84.2%) of
children hospitalized for TB died of TB.
Discussion
There has been a remarkable increase in access to ART
for PLHIV over the past decade, with over 15 million people
receiving treatment by mid-2015 [16]. HIV testing coverage
has also increased, and people living with HIV are accessing
treatment earlier in their disease progression [17]. None-
theless, our review demonstrates that TB remains a leading
cause of hospitalization among PLHIV, particularly in Africa,
South East Asia, and the Western Pacific regions, highlighting
the important continuing contribution of TB as a major cause
of serious HIV-associated morbidity. This was consistent across
all regions, including those with concentrated HIV epidemics.
Key explanations could include the generally late diagnosis of
HIV and presentation with advanced immune deterioration
[18,19], suboptimal adherence to ART and retention in care,
and risk of development of TB even among PLHIV receiving
effective ART [20].
The lack of difference in hospitalizations because of TB
before and after 2009 highlights the continuous burden of TB
on HIV-associated care and points to the need for earlier ART
initiation and expanded ART and IPT coverage. The results
from the recent START trial [21] add to the results from the
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Figure 2. Proportion of hospitalizations among HIV-positive patients that were because of tuberculosis.
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HPTN 052 study [22] in showing that early initiation of ART
has a major impact on TB incidence. Further, recent results
from the TEMPRANO study [23] showed that IPT has an
additive efficacy with respect to the prevention of TB. These
results add to other data that suggest that the two therapies
should be given concomitantly [2426] In this review, no
studies reported IPT use at time of admission, and while this
may reflect a limitation in reporting it is also consistent with
the other studies showing that the scale of implementation
of preventive therapy for TB among PLHIV is still limited [27].
We found very high rates of in-hospital mortality because
of TB. Although recommendations are in place to start ART in
all individuals with a TB diagnosis [28], only 38% of patients
hospitalized with TB were on ART at admission and this may
have contributed to the high in-hospital mortality.
The burden of TB-associated hospital admission could be
reduced through earlier diagnosis of TB in the outpatient
setting [29]. There are challenges in the diagnosis of TB among
PLHIV [30], which can be improved by using Xpert MTB/RIF as
the first line test in those suspected of TB [31]. However, the
scale-up and uptake of Xpert MTB/RIF has so far been limited
[32] despite its capacity to substantially reduce the delay
in diagnosis and treatment initiation [32,33]. Enhancing
the symptom-based routine TB screening among PLHIV and
expediting the diagnosis of TB using Xpert MTB/RIF are
important priorities.
Strengths of this review include a broad search strategy
across multiple databases that allowed a large number of
studies across a range of settings to be identified. We used
random effects models and undertook a number of analyses
to explore the extent of heterogeneity by region, age, diag-
nostic approach and use of ART at admission. The main
limitation of this review is the limited reporting by studies
of ART and IPT status, TB diagnostic method used, TB drug
resistance patterns and the occurrence of TB-immune recon-
stitution inflammatory syndrome, which could potentially
explain observed differences in TB-associated morbidity and
mortality between studies. Another important limitation is
that few studies reported how cause of mortality was
assessed. A recent review of autopsy studies found that TB
was the cause of death in 37% (26 to 49%) of adult deaths
related to HIV/AIDS [7], which is higher than the pooled pro-
portion of TB-associated deaths in this study (25%, 19 to
31%); this difference may reflect both more reliable ascer-
tainment of cause of death and the fact that a proportion of
TB-associated deaths occur without prior hospitalization.
Finally, the quality of the individual studies contributing to
this review was variable, with over half (34 studies) being
retrospective designs, and eight being conference abstracts.
In conclusion, this review underscores the need to strengthen
efforts to improve early diagnosis of HIV, prompt linkage
to care and provision of ART and strengthen TB prevention
activities for people living with HIV, notably through intensi-
fied case finding, provision of IPT and infection control [34].
Considering the high mortality of HIV-positive hospitalized
patients who are found to have TB, national HIV and TB
programmes should embark on joint planning in order to
ensure capacity to diagnose TB among adults and children
living with HIV and to provide effective treatment when TB
is diagnosed.
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